Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook

Published by: AS Insights

Published: Jun. 1, 2004 - 40 Pages

Table of Contents

1. Executive Briefing

2. Introduction

2.1 Definition & Scope

2.2 Currently Marketed Monoclonal Antibody Therapeutics

3. Market Size & Growth Rates

3.1 Global Market for Monoclonal Antibody Therapeutics

3.2 North American Market for Monoclonal Antibody Therapeutics

3.3 European Market for Monoclonal Antibody Therapeutics

3.4 Factors Driving the Market for Mab Therapeutics

3.5 Leading Brands Revenue & Market Shares

4. Leading Brands on the Market

4.1 Remicade (Infliximab)

4.2 Rituxan / MabThera

4.3 Herceptin / Trastuzumab

4.4. Synagis / Palivizumab

4.5 ReoPro (Abciximab)

4.6 Humira (Adalimumab)

4.7 Campath (Alemtuzumab)

4.8 Orthoclone (OKT3 - muromonab-CD3)

4.9 Simulect (Basiliximab)

4.10 Mylotarg (Gemtuzumab ozogamicin)

4.11 Xolair (Omalizumab)

4.12 Zevalin (Ibritumomab tiuxetan)

4.13 Panorax (Edrecolomab - Mab17-1A)

4.14 Bexxar (Tositumomab)

4.15 Raptiva (efalizumab)

4.16 Avastin (bevacizumab)

4.17 Erbitux (Cetuximab)

5. Future Outlook

5.1 Growth Potential

5.2 Monoclonal Antibody Therapeutics Near Commercialization

5.3 Strategic Discussion

List of Tables


1. Global Market for Monoclonal Antibody Therapeutics (1998 - 2003) Market Revenue & Growth Rates

2. Global Market for Monoclonal Antibody Therapeutics - Geographical Segmentation (2003)

3. North American Market for Monoclonal Antibody Therapeutics (1998 - 2003) Market Revenue & Growth Rates

4. European Market for Monoclonal Antibody Therapeutics (1998 - 2003) Market Revenue & Growth Rates

5. Global Market for Monoclonal Antibody Therapeutics (2004 - 2010) Revenue Forecasts

6. Monoclonal Antibody Therapeutics - Leading Brands Market Share (2003)

7. Monoclonal Antibody Therapeutics - Leading Brands Market Revenue (2003)

8. Monoclonal Antibody Therapeutics Available on World Markets (2003)

9. Remicade (Infliximab) (1998 - 2003) Global Revenue & Growth Rates

10. Remicade (Infliximab) (1998 - 2003) North American Market Revenue & Growth Rates

11. Rituxan / MabThera (1998 - 2003) Global Revenue & Growth Rates

12. Rituxan / MabThera (1998 - 2003) North American Market Revenue & Growth Rates

13. Herceptin (Trastuzumab) (1998 - 2003) Global Revenue & Growth Rates

14. Herceptin (Trastuzumab) (1998 - 2003) North American Market Revenue & Growth Rates

15. Synagis (Palivizumab) (1998 - 2003) Global Revenue & Growth Rates

16. ReoPro (Abciximab) (1998 - 2003) Global Revenue & Growth Rates

17. ReoPro (Abciximab) (1998 - 2003) North American Market Revenue & Growth Rates

Abstract

The global market for Monoclonal Antibody (Mab) Therapeutics reached a total of $7.2 billion in 2003. The market has been growing at an impressive compound average annual growth rate of 53% over the previous five years.

The key advantage of Mab Therapeutics is their high levels of specificity for the relevant disease targets. This pinpoint specificity also serves to prevent harm to healthy cells and, hence, typically results in fewer adverse effects compared to other medicines.

Many of the leading pharmaceutical companies have entered the MAb sector, attracted by quicker and less costly development, higher success rates, premium pricing, and a potentially reduced threat from generics.

In 2003, the Mab Therapeutics sector reached an important milestone in its evolution with the launch of Abbott / Cambridge Antibody Technology's Humira, the first fully-human monoclonal antibody (Mab) to enter a major market.

The outlook for monoclonal antibody therapeutics is healthy. The ongoing success of existing products, combined with a bulging pipeline of new products awaiting approval and limited generic erosion, point towards robust growth in this segment.

Industry participants forecast of the market vary widely, however, a consensus is emerging that the market should reach US$26 billion by the end of the decade. This is a conservative estimate implying an average annual growth rate of 18%.

Monoclonal Antibody Therapeutics - Current Market Dynamics and Future Outlook report reviews the current status of the market for monoclonal antibody therapeutics, highlights the differences between regional markets, profiles leading products and their marketing companies and discusses the different windows of opportunities opening in this market.

The report provides figures of market size, growth rates and historical evolution of the global, North American and European Mab Therapeutics markets. It also provides sales and growth rate figures for the following leading monoclonal antibody therapeutics: Remicade, Rituxan / MabThera, Herceptin, Synagis and ReoPro (Abciximab).

The report also discusses the monoclonal antibody therapeutics market outlook, growth potential, attractive areas of growth, technological innovations, products in development and consensus forecasts to the year 2010.

Written with the senior executive needs in mind, Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.